Concentration as a Clinical Instrument — How Dilution Governs Diffusion

Neurotoxin dilution and diffusion are linked by a decision most injectors make without realising they are making it. Reconstitution volume is usually treated as a habit — the number the practice has always used — when it is in fact the main lever an injector has over how far the drug travels from the point of the needle. Dr. Chris Croley, Chief Medical Officer at Empire Medical Training, teaches reconstitution as a treatment-planning decision for exactly this reason: the same unit dose, prepared two different ways, produces two different fields of effect.

This article is about making that choice deliberately. It assumes the arithmetic covered in Empire's pillar resource on units versus volume — that the vial holds a fixed number of units and that diluent volume sets concentration — and moves on to the clinical question: when do you want a tight field, when do you want a wide one, and what governs the answer.

Say what you mean: diffusion, spread and field of effect

Three words get used interchangeably and shouldn't be.

Spread is the physical distribution of injected fluid through tissue at the moment of injection. It is largely mechanical: volume, injection pressure, tissue plane, fascial boundaries, needle bore.

Diffusion is the subsequent movement of toxin molecules through tissue down a concentration gradient. It is slower, occurs over hours, and is influenced by molecular characteristics and local conditions.

Field of effect is what you actually observe — the area of muscle in which clinically meaningful chemodenervation occurs. It is the sum of spread, diffusion, receptor density, dose and the muscle's own anatomy, and it is the only one of the three you can assess in the mirror at two weeks.

Injectors control spread directly through volume. They influence field of effect strongly. They do not control diffusion in any fine-grained way. Being precise about which one you are manipulating keeps expectations honest.

The evidence that volume moves the field

The cleanest demonstration in the aesthetic literature is Hsu, Dover and Arndt, published in Archives of Dermatology in 2004. Ten volunteers with dynamic forehead lines each received a single injection on either side of the forehead, 2.5 cm above the orbital rim in the midpupillary line. Both sides received 5 Units of botulinum toxin type A. One side received it in 0.25 mL; the other in 0.05 mL — a fivefold difference in injected volume at an identical dose. Sides were randomised, and subjects were assessed at 14 days for the area of rhytid effacement during active contraction.

The result: the area affected was 50% greater on the larger-volume side in 9 of 10 subjects, with a mean affected area of 6.05 cm² versus 4.12 cm². The authors also noted the effaced area was oval rather than round, with average width exceeding average height, indicating that spread is not isotropic — it follows tissue architecture and is altered by muscular contraction at the injected site.

Two conclusions follow, and both are practical. Volume materially changes how much muscle you affect at a fixed dose. And the shape of the field is not a circle you can draw on a face chart; it is directional, and it follows the muscle.

Croley teaches the same relationship from the clinical end: "If I inject a large volume into this area, it can diffuse or move over into that area. So in those situations, we'd like to use something with a very tight concentration."

The decision framework

Reconstitution should answer five questions before it answers "what do we always use?"

1. How big is the target, and how much of it do you need to affect? A frontalis spanning most of the forehead is a large, broad, superficial target where a degree of spread between injection points is desirable — it is what produces an even brow rather than a scalloped one. A depressor anguli oris is a thin strap muscle a few millimetres thick sitting immediately beside a muscle you must not weaken. Large diffuse target, looser field. Small discrete target, tighter field.

2. What is immediately next to it, and what happens if you hit it? This is the question that should carry the most weight. Not all neighbouring structures carry equal penalty. Spread from a corrugator injection into the frontalis produces a brow position change the patient may or may not like. Spread from a glabellar injection through the orbital septum toward levator palpebrae superioris produces eyelid ptosis lasting weeks. Spread from the depressor anguli oris into the depressor labii inferioris produces an asymmetric smile and lower lip incompetence that is highly visible in speech. Weight your concentration choice by the consequence of error, not just by its probability.

3. How many injection points are you using? Volume and point count are substitutes for each other. Five points at 0.1 mL and ten points at 0.05 mL deliver the same total fluid, but the second distributes it more evenly and depends less on spread to cover the territory. A tighter concentration with more points is frequently a better answer than a looser concentration with fewer, particularly in a field where you want even coverage without unpredictable reach at the margins.

4. What plane are you in? Fluid injected into a loose areolar plane travels further than fluid deposited within a dense muscle belly. Intradermal placement behaves differently again. Depth and plane modulate the effect of any given volume, which is why two injectors using identical concentrations can produce different fields.

5. What is the cost of underdosing versus overreaching? In a first-time patient, or in a region where the failure mode is cosmetically obvious and slow to resolve, a tight field with a planned two-week review and top-up is the conservative path. In a treatment where partial coverage means visible asymmetry, being too conservative has its own cost.

The two ends of the range

Tighter concentration — less diluent, less volume per unit.

Indicated where the target is small, the neighbour is dangerous, and precision matters more than coverage. Croley's teaching example is the perioral field: "Maybe we would use something like a one millilitre reconstitution. So for me to deliver two units I would only go to this part of the syringe. Tiny, tiny dose. So it doesn't go over here."

At a 1 mL reconstitution of a 100 Unit vial you hold 10 Units per 0.1 mL, so a 2 Unit dose is 0.02 mL. At the more common 2.5 mL reconstitution, 2 Units is 0.05 mL — two and a half times the deposited fluid at the same dose. In a corridor where the muscle you must protect sits a few millimetres away, that difference is the whole treatment. Empire's companion resource on the depressor anguli oris corridor works that case through in detail.

The trade-off is real: very small volumes are harder to draw accurately, harder to read on the syringe, and proportionally more sensitive to dead-space loss. Concentrated preparations demand better syringe discipline, which is its own resource in this cluster.

Looser concentration — more diluent, more volume per unit.

Indicated where the target is a surface or a broad sheet rather than a discrete belly, and where the goal is even coverage across territory. The on-label example is primary axillary hyperhidrosis, where the BOTOX label instructs a dilution of 100 Units in 4 mL — 2.5 Units per 0.1 mL — with 50 Units per axilla delivered intradermally across 10 to 15 sites in 0.1 to 0.2 mL aliquots.

Croley reaches the same place by reasoning rather than recipe: "When we start talking about areas like hyperhidrosis or sweating... in those situations, we want that neurotoxin to spread out over a wide surface area, so we get the effect of it. So how do we deliver those number of units over a wide surface area? We put more fluid."

The trade-off is loss of edge control. A wide field is exactly what you want across an axilla and exactly what you do not want beside the depressor labii inferioris.

Three things to hold alongside it

Concentration is the main lever, and these three points are what keep it working as one.

Dilution works alongside the other variables, not instead of them. Dose, injection depth, plane, needle angle, injection speed, point spacing and the patient's own muscle anatomy all contribute to the observed field. Standardising your reconstitution makes the rest of them legible, which is the point of standardising it.

Cross-product diffusion differences are contested. Whether one botulinum toxin formulation intrinsically spreads further than another at matched conditions has been argued for two decades, and the literature is not settled — studies differ on dose matching, concentration matching, endpoint and measurement method. It is not a fact an injector should build a protocol on. What is well supported is the within-product relationship Hsu and colleagues measured: for a given product, more volume at the same dose means a larger field.

Label concentrations are studied concentrations. When you vary reconstitution away from the label, you are extrapolating from the efficacy and safety data the product was approved on. That is routine and often reasonable, but it should be conscious. The label's chosen concentration is a studied condition, not an arbitrary default.

These figures reflect Dr. Croley's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

Putting it into protocol

A practice that treats concentration as an instrument rather than a habit generally ends up with two or three standard preparations rather than one, each matched to a class of treatment: a working concentration for routine upper-face work, a concentrated preparation for precision perioral and small-muscle work, and a dilute preparation for wide-field and intradermal indications.

Each one gets labelled on the vial in units per 0.1 mL. Each one gets its own written conversion table so nobody is doing division at the chairside. And every treatment note records the concentration alongside the unit dose, because a dose without a concentration is not reproducible at the next visit.

Injectors who want to work through concentration selection against real anatomy can do so in Empire's Anatomical Based Aesthetics Training and Cosmetic Neurotoxins Training workshops. Empire's material on frontalis dosing and injection site mapping covers the regional planning this framework feeds into, and Complete Botox Training covers the vial work itself.

Related guides in this cluster

Part of Neurotoxin Reconstitution and Dosing.

Clinical GuideOn-Label Reconstitution Across the US Neurotoxins — A Reference Table for InjectorsA complete on-label neurotoxin reconstitution chart for Botox, Dysport, Xeomin, Jeuveau and Daxxify — vial sizes, diluent volumes and u Clinical GuideWhy a Unit of Botox Is Not a Unit of DysportBotox units vs Dysport units are not the same measure. Units are defined by each manufacturer's own potency assay — here is why no conv Clinical GuideBacteriostatic vs Preservative-Free Saline — What the Benzyl Alcohol Actually DoesBacteriostatic saline for neurotoxin reconstitution is off-label but well studied. What benzyl alcohol does to injection pain, potency